FORTRESS BIOTECH INC (FBIO) Stock Price, Quote, News and Overview
NASDAQ:FBIO - Nasdaq - US34960Q3074 - Common Stock - Currency: USD
FBIO Quote, Performance and Key Statistics
1.62
0 (0%)
The current stock price of FBIO is 1.62 USD. In the past month the price decreased by -10.99%. In the past year, price decreased by -6.9%.
FBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FBIO
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 186 full-time employees. The company went IPO on 2011-11-17. The firm has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
Company Info
FORTRESS BIOTECH INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10014 US
CEO: Lindsay A. Rosenwald
Employees: 186
Company Website: https://www.fortressbiotech.com/
Investor Relations: https://www.fortressbiotech.com/investors
Phone: 17816524500
FORTRESS BIOTECH INC / FBIO FAQ
What is the stock price of FORTRESS BIOTECH INC today?
The current stock price of FBIO is 1.62 USD.
What is the ticker symbol for FORTRESS BIOTECH INC stock?
The exchange symbol of FORTRESS BIOTECH INC is FBIO and it is listed on the Nasdaq exchange.
On which exchange is FBIO stock listed?
FBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FORTRESS BIOTECH INC stock?
9 analysts have analysed FBIO and the average price target is 15.3 USD. This implies a price increase of 844.44% is expected in the next year compared to the current price of 1.62. Check the FORTRESS BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FORTRESS BIOTECH INC worth?
FORTRESS BIOTECH INC (FBIO) has a market capitalization of 44.71M USD. This makes FBIO a Nano Cap stock.
How many employees does FORTRESS BIOTECH INC have?
FORTRESS BIOTECH INC (FBIO) currently has 186 employees.
What are the support and resistance levels for FORTRESS BIOTECH INC (FBIO) stock?
FORTRESS BIOTECH INC (FBIO) has a support level at 1.5 and a resistance level at 1.65. Check the full technical report for a detailed analysis of FBIO support and resistance levels.
Is FORTRESS BIOTECH INC (FBIO) expected to grow?
The Revenue of FORTRESS BIOTECH INC (FBIO) is expected to decline by -16.96% in the next year. Check the estimates tab for more information on the FBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FORTRESS BIOTECH INC (FBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FBIO, evaluating the profitability, health, valuation and growth aspects
- FORTRESS BIOTECH INC (FBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FORTRESS BIOTECH INC (FBIO) Sales and EPS estimates to see what analysts future expectations are.
- FORTRESS BIOTECH INC (FBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FORTRESS BIOTECH INC (FBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- FORTRESS BIOTECH INC (FBIO) Stock Chart to make your own analysis
- FORTRESS BIOTECH INC (FBIO) Latest news and press-releases to stay up to date.
Does FORTRESS BIOTECH INC (FBIO) stock pay dividends?
FBIO does not pay a dividend.
When does FORTRESS BIOTECH INC (FBIO) report earnings?
FORTRESS BIOTECH INC (FBIO) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of FORTRESS BIOTECH INC (FBIO)?
FORTRESS BIOTECH INC (FBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.8).
What is the Short Interest ratio of FORTRESS BIOTECH INC (FBIO) stock?
The outstanding short interest for FORTRESS BIOTECH INC (FBIO) is 17.94% of its float. Check the ownership tab for more information on the FBIO short interest.
FBIO Technical Analysis
FBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBIO. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
FBIO Financial Highlights
Over the last trailing twelve months FBIO reported a non-GAAP Earnings per Share(EPS) of -3.8. The EPS increased by 68.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.27% | ||
| ROE | -271.89% | ||
| Debt/Equity | 2.48 |
FBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to FBIO. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 63.44% and a revenue growth -16.96% for FBIO